Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 5INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 1Glioblastoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × fotemustine × Clear all
NCT01069627 2018-12-06

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Hoffmann-La Roche

Phase 2 Completed
20 enrolled 21 charts
Dermatologic

Melanoma

NCT01474239 2016-03-15

A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma

Hoffmann-La Roche

Phase 2 Completed
91 enrolled 19 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡